Amgen Combination Therapy Cuts Death Risk 58% in Lung Cancer Trial
Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% versus Imfinzi alone in patients with extensive-stage small cell lung cancer, according to trial data presented at a medical meeting.
By Deena BeasleyAmgen's NASDAQ:AMGN Imdelltra used in combination with AstraZeneca's LSE:AZN immunotherapy Imfinzi reduced the risk of death by 58% compared to the Astra drug alone in patients with extensive-stage small cell lung cancer, according to data from a study presented at a major medical m…